PCN105 COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB VERSUS NIVOLUMAB AS THE FIRST-LINE TREATMENT FOR ADVANCED AND METASTATIC NON-SMALL CELL LUNG CANCER IN UNITED KINGDOM
2020
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI